Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) has announced plans to report its financial results for the first fiscal quarter ended December 31, 2022, on February 7, 2023, after market close. The management will conduct a conference call at 4:30 p.m. ET to discuss these results and provide updates on ongoing research and development initiatives. Enanta focuses on developing small molecule drugs targeting viral infections, including COVID-19, RSV, and hepatitis B. It receives funding through royalties from its collaboration with AbbVie, particularly from the HCV treatment drug, Glecaprevir.

Positive

• Strong pipeline targeting viral infections, including COVID-19 and RSV.
• Research funded by royalties from HCV collaboration with AbbVie.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information

The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website. To participate by phone, please register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005112/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals report its Q1 2023 financial results?

Enanta Pharmaceuticals plans to report its Q1 2023 financial results on February 7, 2023.

What time is the Enanta Pharmaceuticals conference call?

The conference call is scheduled for 4:30 p.m. ET on February 7, 2023.

What disease targets is Enanta Pharmaceuticals focusing on?

Enanta Pharmaceuticals is focusing on viral infections including SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV), and hepatitis B virus (HBV).

How does Enanta Pharmaceuticals fund its research?

Enanta Pharmaceuticals funds its research through royalties from the hepatitis C virus products developed in collaboration with AbbVie.